PortfoliosLab logoPortfoliosLab logo
BIIB vs. GILD
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BIIB vs. GILD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Biogen Inc. (BIIB) and Gilead Sciences, Inc. (GILD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BIIB achieves a 11.63% return, which is significantly higher than GILD's 5.84% return. Over the past 10 years, BIIB has underperformed GILD with an annualized return of -3.81%, while GILD has yielded a comparatively higher 7.70% annualized return.


BIIB

1D
0.25%
1M
3.87%
YTD
11.63%
6M
7.95%
1Y
48.98%
3Y*
-13.37%
5Y*
-7.25%
10Y*
-3.81%

GILD

1D
0.15%
1M
-3.22%
YTD
5.84%
6M
6.65%
1Y
21.64%
3Y*
22.54%
5Y*
18.21%
10Y*
7.70%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BIIB vs. GILD - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
BIIB
Biogen Inc.
11.63%15.09%-40.91%-6.55%15.42%-2.02%-17.48%-1.39%-5.54%12.34%
GILD
Gilead Sciences, Inc.
5.84%36.59%18.68%-1.99%23.63%29.95%-6.70%7.88%-9.92%2.96%

Correlation

The correlation between BIIB and GILD is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.29

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.39

Correlation (10Y)
Calculated over the trailing 10-year period

0.44

Correlation (All Time)
Calculated using the full available price history since Jan 23, 1992

0.38

The correlation between BIIB and GILD shifts across timeframes, from 0.29 (1 year) to 0.44 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

EPS

BIIB:

$12.48

GILD:

$7.35

PE Ratio

BIIB:

15.74

GILD:

17.58

PEG Ratio

BIIB:

1.09

GILD:

0.04

PS Ratio

BIIB:

2.19

GILD:

5.45

Total Revenue (TTM)

BIIB:

$9.86B

GILD:

$29.74B

Gross Profit (TTM)

BIIB:

$5.06B

GILD:

$18.74B

EBITDA (TTM)

BIIB:

$2.24B

GILD:

$12.88B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BIIB vs. GILD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIIB
BIIB Risk / Return Rank: 8181
Overall Rank
BIIB Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
BIIB Sortino Ratio Rank: 7979
Sortino Ratio Rank
BIIB Omega Ratio Rank: 7575
Omega Ratio Rank
BIIB Calmar Ratio Rank: 8585
Calmar Ratio Rank
BIIB Martin Ratio Rank: 8585
Martin Ratio Rank

GILD
GILD Risk / Return Rank: 6565
Overall Rank
GILD Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
GILD Sortino Ratio Rank: 6363
Sortino Ratio Rank
GILD Omega Ratio Rank: 5959
Omega Ratio Rank
GILD Calmar Ratio Rank: 6666
Calmar Ratio Rank
GILD Martin Ratio Rank: 6767
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIIB vs. GILD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Gilead Sciences, Inc. (GILD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BIIBGILDDifference
Sharpe ratioReturn per unit of total volatility

+0.66

Sortino ratioReturn per unit of downside risk

+0.87

Omega ratioGain probability vs. loss probability

1.26

1.16

+0.10

Calmar ratioReturn relative to maximum drawdown

3.43

1.23

+2.20

Martin ratioReturn relative to average drawdown

8.40

3.07

+5.33

BIIB vs. GILD - Sharpe Ratio Comparison

The current BIIB Sharpe Ratio is 1.48, which is higher than the GILD Sharpe Ratio of 0.83. The chart below compares the historical Sharpe Ratios of BIIB and GILD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BIIBGILDDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.48

0.83

+0.66

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.19

0.76

-0.95

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.09

0.30

-0.40

Sharpe Ratio (All Time)

Calculated using the full available price history

0.23

0.39

-0.16

Drawdowns

BIIB vs. GILD - Drawdown Comparison

The maximum BIIB drawdown since its inception was -89.98%, which is greater than GILD's maximum drawdown of -70.83%. Use the drawdown chart below to compare losses from any high point for BIIB and GILD.


Loading charts...

Drawdown Indicators


BIIBGILDDifference

Max Drawdown

Largest peak-to-trough decline

-89.98%

-70.83%

-19.15%

Max Drawdown (1Y)

Largest decline over 1 year

-14.34%

-17.65%

+3.31%

Max Drawdown (3Y)

Largest decline over 3 years

-63.82%

-26.59%

-37.23%

Max Drawdown (5Y)

Largest decline over 5 years

-72.66%

-26.59%

-46.07%

Max Drawdown (10Y)

Largest decline over 10 years

-72.66%

-30.47%

-42.19%

Current Drawdown

Current decline from peak

-58.73%

-16.62%

-42.11%

Average Drawdown

Average peak-to-trough decline

-36.61%

-22.16%

-14.45%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.85%

7.06%

-1.21%

Volatility

BIIB vs. GILD - Volatility Comparison

Biogen Inc. (BIIB) has a higher volatility of 9.84% compared to Gilead Sciences, Inc. (GILD) at 7.26%. This indicates that BIIB's price experiences larger fluctuations and is considered to be riskier than GILD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BIIBGILDDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.84%

7.26%

+2.58%

Volatility (6M)

Calculated over the trailing 6-month period

24.13%

18.55%

+5.58%

Volatility (1Y)

Calculated over the trailing 1-year period

33.21%

26.31%

+6.90%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

38.38%

24.03%

+14.35%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

41.47%

25.49%

+15.98%

Dividends

BIIB vs. GILD - Dividend Comparison

BIIB has not paid dividends to shareholders, while GILD's dividend yield for the trailing twelve months is around 2.47%.


PositionTTM20252024202320222021202020192018201720162015
BIIB
Biogen Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
GILD
Gilead Sciences, Inc.
2.47%2.57%3.33%3.70%3.40%3.91%4.67%3.88%3.65%2.90%2.57%1.27%

Financials

BIIB vs. GILD - Financials Comparison

This section allows you to compare key financial metrics between Biogen Inc. and Gilead Sciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


2.00B3.00B4.00B5.00B6.00B7.00B8.00B20222023202420252026
2.48B
6.96B
(BIIB) Total Revenue
(GILD) Total Revenue
Values in USD except per share items

BIIB vs. GILD - Profitability Comparison

The chart below illustrates the profitability comparison between Biogen Inc. and Gilead Sciences, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
1.1%
Portfolio components
BIIB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported a gross profit of 0.00 and revenue of 2.48B. Therefore, the gross margin over that period was 0.0%.

GILD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a gross profit of 79.20M and revenue of 6.96B. Therefore, the gross margin over that period was 1.1%.

BIIB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported an operating income of 0.00 and revenue of 2.48B, resulting in an operating margin of 0.0%.

GILD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported an operating income of 2.59B and revenue of 6.96B, resulting in an operating margin of 37.2%.

BIIB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported a net income of 319.50M and revenue of 2.48B, resulting in a net margin of 12.9%.

GILD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a net income of 2.02B and revenue of 6.96B, resulting in a net margin of 29.0%.


Frequently Asked Questions


BIIB and GILD have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BIIB has higher volatility (9.84%) compared to GILD (7.26%). In terms of maximum drawdown, BIIB dropped -89.98% vs GILD's -70.83%.

BIIB currently has the higher Sharpe Ratio (1.48 vs 0.83), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BIIB and GILD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer